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Abstract
Vaccine efficacy (VE) estimates are crucial for assessing the suitability of dengue vaccine
candidates for public health implementation, but efficacy trials are subject to a known bias to
estimate VE toward the null if heterogeneous exposure is not accounted for in the analysis
of trial data. In light of many well-characterized sources of heterogeneity in dengue virus
(DENV) transmission, our goal was to estimate the potential magnitude of this bias in VE
estimates for a hypothetical dengue vaccine. To ensure that we realistically modeled hetero-
geneous exposure, we simulated city-wide DENV transmission and vaccine trial protocols
using an agent-based model calibrated with entomological and epidemiological data from
long-term field studies in Iquitos, Peru. By simulating a vaccine with a true VE of 0.8 in 1,000
replicate trials each designed to attain 90% power, we found that conventional methods
underestimated VE by as much as 21% due to heterogeneous exposure. Accounting for the
number of exposures in the vaccine and placebo arms eliminated this bias completely, and
the more realistic option of including a frailty term to model exposure as a random effect
reduced this bias partially. We also discovered a distinct bias in VE estimates away from the
null due to lower detectability of primary DENV infections among seronegative individuals in
the vaccinated group. This difference in detectability resulted from our assumption that pri-
mary infections in vaccinees who are seronegative at baseline resemble secondary infec-
tions, which experience a shorter window of detectable viremia due to a quicker immune
response. This resulted in an artefactual finding that VE estimates for the seronegative
group were approximately 1% greater than for the seropositive group. Simulation models of
vaccine trials that account for these factors can be used to anticipate the extent of bias in
field trials and to aid in their interpretation.
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Introduction
An estimated 390 million people worldwide experience dengue virus (DENV) infections each
year, with approximately 96 million of those showing clinically apparent symptoms [1]. Only
one dengue vaccine (Dengvaxia, Sanofi Pasteur) has been licensed to date, although safety con-
cerns have limited its rollout [2]. Beyond Dengvaxia, 22 investigational dengue vaccines are at
various stages of development, with six of them in clinical trials [3]. Two tetravalent vaccines
have advanced to phase-III clinical trials to evaluate vaccine efficacy against symptomatic,
virologically-confirmed dengue disease [4,5]. In addition, 14 investigational Zika vaccines are
under development, some of which may also advance to late-phase trials [6]. Late-phase vac-
cine trials for dengue, Zika, and chikungunya—three viruses with a common mosquito vector
in Aedes aegypti—share a number of common challenges.
A major challenge for vaccine trials for these diseases derives from the observation that
their transmission is characterized by extensive spatial and temporal heterogeneity. For exam-
ple, epidemiological studies of dengue in both rural [7] and urban [8] settings in Thailand
showed that transmission tends to occur focally at spatial scales of 1 km or less and can be
much more intense at some times than others. Similar observations are being made for Zika
and chikungunya [9,10]. Some of the complications posed to vaccine trials by such strong spa-
tial and temporal heterogeneity include achieving balanced randomization with respect to
exposure across trial arms and correctly anticipating exposure rates in advance of a trial.
Another complication for vaccine trials for these diseases also derives from heterogeneity in
transmission, but at much finer scales. Field studies [11,12] have shown that patterns of Ae. aegypti
blood-feeding are extremely heterogeneous; i.e., most of the mosquito bites are concentrated on a
few, while other people are rarely bitten [13]. These heterogeneities apply to individuals within a
single household and become compounded even further [14] when layered on top of house-to-
house variation in Ae. aegypti densities [15] and complex patterns of human [16,17] and mosquito
[18] movement, which affect human-mosquito contact. This fine-scale variation results in hetero-
geneity in the number of DENV exposures that trial participants experience, which can lead to
bias in estimates of vaccine efficacy for susceptibility (VES) [19] for “leaky” vaccines, which confer
partial protection to all vaccinees rather than full protection to a subset [20]. This type of bias
applies to VES estimates derived using survival methods, such as Cox regression models, unless
trial participants experience homogeneity in exposure [21,22]. In the presence of heterogeneities
in exposure, frailty models have been proposed to reduce bias in VES estimates [21]. Measuring
exposure or collecting data on risk factors can also help in reducing this bias [22].
Because heterogeneity in exposure is known to induce bias in VES estimates for leaky vac-
cines and because there is so much heterogeneity in DENV transmission that would be nearly
impossible to account for explicitly in a trial, we used a simulation-based approach to assess
the extent to which heterogeneous exposure may bias VES estimates for dengue vaccines.
Leveraging detailed historical understanding of DENV transmission in Iquitos, Peru, we used
this model to explore plausible outcomes for hypothetical vaccine efficacy trials that were sim-
ulated as if they took place at a specific point in time during the past in Iquitos. This exercise is
an initial case study on which additional analyses can be developed for other specific settings
of interest as data from other vaccine trial sites become available and amenable to modeling.
Methods
Trial overview
We designed a hypothetical, individually randomized phase-III trial of a generic dengue vaccine.
The aim of the trial was to evaluate the vaccine efficacy for susceptibility (VES) as a measure of the
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protective effects of vaccination against the first symptomatic, virologically-confirmed case of den-
gue caused by any DENV serotype during simulated vaccine trials in Iquitos, Peru. A virologi-
cally-confirmed dengue case was defined as febrile illness with temperature� 38˚C for at least
two consecutive days and a positive result from a reverse-transcriptase polymerase chain reaction
(RT-PCR) from a blood sample. This endpoint has been used in phase-III dengue vaccine trials
and is recommended by the WHO [23]. We chose to simulate the trial in Iquitos because of its
long history of epidemiological studies of dengue, which provide a unique opportunity to parame-
terize and validate detailed models of DENV transmission [16,24–27]. Iquitos is a city of approxi-
mately 370,000 inhabitants, located in the Amazon Basin and accessible only by boat or airplane.
We simulated the active phase of our hypothetical dengue vaccine trials comparable to previ-
ous and ongoing trials [5,28–32] (Table 1), such that ours consisted of regular contacts with
study participants for at least 13 months after completion of a full course of vaccination (two
doses, two months apart). Simulated trial participants were randomly assigned to a placebo or
vaccine arm in a 1:1 ratio. We assumed that the placebo conferred no protection against clinical
endpoints and that the vaccine conferred some level of protection defined as an input of the
model and estimated as VES with the data collected from the trial. In all simulations, we initial-
ized the trial on June 26, 2009. The period thereafter was characterized by a relatively high force
of infection of multiple DENV serotypes [27], which would have been ideal for a trial.
Vaccine model
We modeled a hypothetical vaccine with a per-exposure protection (PEP) that represents the
reduction in risk of disease that the vaccine confers to an individual following a single
Table 1. Characteristics of four vaccine trial designs for dengue vaccines, in addition to our virtual trial.
Variable Sanofi CYD14 [28] Sanofi CYD 15 [30] Takeda
[5,32]
Butantan
[4,31]
Virtual trial
Sample size 10,278 20,875 20,100 16,944 2,324�
Number of sites 12 22 Not specified Not specified 1
Vaccine:control
ratio
2:1 2:1 1:1 2:1 1:1
Power 0.90 0.90 - - 0.90
Control Placebo Placebo Placebo Placebo Placebo
Target efficacy 0.70 - - 0.80 0.80
Lower bound of
vaccine efficacy
0.25 0.25 - 0.25 0.30
Age groups 2–5,6–11, 12–14 9–11, 12–16 4–16 2–6, 7–17,18–59 5–17, 18–45
Primary endpoint Symptomatic virologically-
confirmed dengue disease
Symptomatic virologically-
confirmed dengue disease
Symptomatic virologically-
confirmed dengue disease
Symptomatic virologically-
confirmed dengue disease
Symptomatic virologically-
confirmed dengue disease
Vaccination
schedule
Months: 0, 6, 12 Months: 0, 6, 12 Days: 1, 90 Day 1 Days: 1, 60
Expected cases 57 57 120 24 68
Minimum
timeframe to
estimate VE
1 year 1 year 1 year 1 year 1 year
Statistical analysis Incidence density Incidence density Survival analysis Incidence density Survival analysis
Safety follow-up 5 years 5 years 4.75 years 5 years -
Test for baseline
DENV serology
Subset Subset Yes - Yes
�Baseline scenario
https://doi.org/10.1371/journal.pone.0210041.t001
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exposure to DENV. The vaccine reduces the risk of two separate events: successful DENV
infection conditional on exposure (RRinf|exp) and clinically apparent dengue fever conditional
on DENV infection (RRdis|inf), such that
PEP ¼ 1   RRrinfjexpRR
1  r
disjinf ; ð1Þ
where RRinf|exp, RRdis|inf, and ρ are specified as inputs to the model. Our default assumption
was that the vaccine protects equally against infection conditional on exposure and against dis-
ease conditional on infection (ρ = 0.5). Our default assumptions about RRinf|exp and RRdis|inf
were that they both equaled 0.447, consistent with an exploratory PEP value of 0.8 as assumed
in planning for the ongoing Butantan trial [31]. In our model, the vaccine does not modify the
probability of progressing from symptomatic to severe disease, because the focus of our analy-
sis is on the primary endpoint of virologically-confirmed disease rather than the more severe
outcomes that can sometimes be associated with dengue. Even though dengue vaccines seem
to have heterogeneous effects in protection [29], we assumed constant protection with respect
to time since inoculation, serotype, and serostatus, to simplify the vaccine model and to isolate
the effect of heterogeneous exposure from the effect of heterogeneous vaccine protection.
Virtual trial procedures
Our virtual phase-III trial featured three main processes: recruitment, vaccination, and surveil-
lance. These processes comprise eight specific procedures, which are depicted in Fig 1. The
recruitment phase included (1) enrollment of participants and (2) serological testing to assess
for previous DENV infection. Vaccination included (3,4) administration of two doses of vac-
cine two months apart. Next, study personnel (5) captured cases during weekly phone calls to
Fig 1. Modeling framework and trial procedures. DENV is transmitted by individual mosquitoes that are found indoors. Humans move daily to
different types of locations within the city. Infectious mosquitoes transmit DENV through bites to individuals susceptible to the infecting serotype
who are present at a location at the same time as mosquitoes seeking a blood meal. The trial consists of eight procedures listed in the figure. The
top curve shows the timing of these procedures in reference to DENV transmission dynamics, and the bottom cartoon depicts each of the
procedures.
https://doi.org/10.1371/journal.pone.0210041.g001
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participants, and a proportion of (6) individuals with symptoms notified trial personnel. Con-
firmation of DENV infection (7) was attempted with a serotype-specific RT-PCR test, and (8)
confirmed cases were recorded in surveillance reports. The trial considers only the first case of
symptomatic dengue for each individual in estimates of VES.
Recruitment. We enrolled simulated trial participants during the first two months of the
trial. We randomly selected a subset of the simulated population who were 5–45 years old (y.
o.). The number of participants was consistent with the desired sample size to achieve a statisti-
cal power of 0.9[33], as described in S1 Text. Because DENV exposure differs between children
and adults, we recruited participants in such a way that half were children (5–17 y.o.) and half
were adults (18–45 y.o.). Within each of those two groups, each participant was randomly
assigned to the vaccine or placebo arm on a 1:1 basis. Next, a participant’s pre-existing sero-
positivity to DENV was recorded, which we assumed could be measured accurately for all trial
participants. Individuals without previous exposure to DENV were classified as seronegative
and individuals with previous exposure to any of the four DENV serotypes were classified as
seropositive, without specification of the number or type of the previous DENV infections.
Vaccination. In the simulation, participants received the first dose of the vaccine or pla-
cebo on the day of enrollment. The vaccine conferred PEP defined by the vaccine model,
whereas the placebo conferred no protection against infection or disease. Each participant
received two doses of vaccine or placebo within sixty days of enrollment. This choice was inter-
mediate between two dengue vaccines currently in phase-III trials (Takeda: two doses 90 days
apart [32]; Butantan: one dose [31]). We assumed that the full PEP was conferred by the first
dose, its longevity boosted by the second dose, and that all trial participants received both
doses on schedule. Consistent with observations of modest efficacy despite high immunoge-
nicity in the only dengue vaccine for which efficacy has been assessed [34] and with assump-
tions of a model developed by a dengue vaccine manufacturer [35], we assumed that the
vaccine was leaky: i.e., partial protection applies uniformly to all vaccinees, as opposed to full
protection of a subset of vaccinees.
Surveillance. Surveillance started on the day on which the first dose of vaccine was
administered, but cases used for the VES analysis were restricted to those that occurred 28 days
or more after administration of the second dose, similar to the protocol for the CYD-TDV tri-
als [36]. The surveillance system captured symptomatic cases in two different ways: weekly
phone calls to trial participants by trial personnel and self-reporting. Weekly active surveil-
lance contacted participants to inquire about disease symptoms experienced since the last con-
tact with the surveillance system. Half of the individuals with symptoms of dengue fever
reported their symptoms during the weekly surveillance phone calls or sought care, which
allowed for laboratory diagnosis. Everyone with severe dengue reported their symptoms to the
surveillance system. The probability of self-reporting mild dengue cases was higher than esti-
mates of this probability under circumstances outside the context of a trial [37] (5–15%), given
that we expect that people would be more likely to use free healthcare provided as part of their
participation in the trial. Some DENV infections go undetected because they are asymptomatic
or are not virologically-confirmed by the surveillance system. Because these infections are not
detected by the surveillance system, their enrollment status in the trial remains unchanged. To
confirm the presence of DENV, we simulated an RT-PCR test in participants with two conse-
cutive days of symptoms and up to five days after symptom onset in agreement with current
guidelines [38].
To simulate virological confirmation of cases, we modeled the sensitivity of a RT-PCR test
as a function of time since symptom onset. To obtain such a function, we first obtained 3,000
simulated viremia trajectories from a model of viremia dynamics for primary and post-pri-
mary DENV infections that was fitted to data from individuals enrolled in a clinical study in
Biased efficacy estimates in dengue vaccine trials: A simulation study
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Vietnam [39]. We then applied a fixed limit of detection (LOD) of 10 cDNA copies per ml to
the simulated viremia trajectories and recorded the proportion of those 3,000 simulated trajec-
tories that exceeded that LOD at a given time since symptom onset, which we regarded as the
sensitivity of RT-PCR at a given time since symptom onset. We then fitted the function
SiðtÞ ¼
1
1þ e  ðbi1þbi2 tÞ
ð2Þ
to the simulated values of sensitivity t days after symptom onset in primary and post-primary
infections i using the optim function in R [40], obtaining curves depicted in S1 Fig. We assumed
that viremia trajectories corresponding to post-primary infections also applied to vaccinated indi-
viduals, given that both should exhibit an antibody response to DENV infection that would result
in a shortening of DENV infection and, thus, a shorter window of detectability by RT-PCR.
Statistical analyses
We used surveillance records resulting from a given virtual vaccine trial to estimate VES based
on the timing of when trial participants attained the primary endpoint as detected by the sur-
veillance system. The model simulated censored observations; i.e., some individuals dropped
out of the trial before being infected, whereas others finished the trial without being exposed to
DENV. Ignoring this feature of the data can result in overestimation of vaccine efficacy [19].
We estimated the vaccine efficacy for susceptibility (VES) as a measure of how protective the
vaccine was against disease [19]. VES was calculated based on three approaches: incidence
rates, survival methods, and transmission probability. Based on incidence rates, VES,IR was cal-
culated as
VES;IR ¼ 1  
cv=yv
cp=yp
; ð3Þ
where c represents the number of cases detected in each arm of the study, y the number of per-
son-years within the trial, and the subscripts v and p represent the vaccine and placebo arms,
respectively [19]. To calculate VES based on survival methods, we estimated VES,Cox with a
Cox model in R [40] using the coxph function with default settings [41]. The survival model
was implemented with the data represented by the time to first event (or follow-up time) and a
binary variable for PCR positivity. In an attempt to account for heterogeneous exposure within
the trial, we also considered the addition of a frailty expression—in which heterogeneity in
exposure was defined as a random effect by a gamma distribution—to the Cox-regression
model and estimated VES,frailty using the same coxph function in R with an additional frailty
term specified as frailty(ID, distribution = "gamma").
The above methods do not require information about the level of exposure of individuals in
the trial. Such measures are often used in phase-III trials to measure VES because information
on exposure to infection may be unfeasible to obtain in field trials. This task is particularly dif-
ficult for mosquito-borne diseases, because individual mosquito bites would need to be
recorded to estimate the level of exposure of trial participants. Our model allowed us to record
the exact number of exposures that every individual experienced during the trial, defined as an
infectious bite received by a susceptible human. Knowledge on the exact number of exposures
allowed us to estimate VES based on the probability of transmission ‘p’, which should be robust
to heterogeneous exposure. The measure VES,p was defined as
VES;p ¼ 1  
cv=nv
cp=np
; ð4Þ
Biased efficacy estimates in dengue vaccine trials: A simulation study
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where cv and cp represent the number of cases in the vaccine and placebo arm, respectively,
and nv and np represent the total number of exposures in the vaccine and placebo arms, respec-
tively [19]. Comparison between this and other VES measures was used to aid in the interpre-
tation of our results.
Model overview
We simulated vaccine trials using an agent-based model of DENV transmission that simulates
the transmission dynamics of DENV in a population of 200,000 in a core population area of
Iquitos, Peru [42,43]. Our model includes simulated daily human movement patterns cali-
brated to data from retrospective, semi-structured interviews of residents in Iquitos [44,45].
This model has been demonstrated to reproduce the dynamics of all four DENV serotypes
[42] and was used to investigate the epidemiological impacts of hypothetical vaccination cam-
paigns to project the population-level impact of Dengvaxia [46,47]. Because a formal descrip-
tion of the version of the transmission model that was used here has been published elsewhere
[42], we provide an overview of its key features and assumptions in S2 Text.
Model calibration
We used parameter estimates from the literature wherever possible (Table 2) and calibrated
the values of unknown parameters so as to allow the model to generate patterns of transmis-
sion within the study area consistent with time-varying incidence of infection estimates from a
longitudinal cohort study [27]. Three sets of parameters were calibrated through this process:
(1) serotype-specific population immunity on 1 January 2000, when estimates of time-varying,
serotype-specific incidence of infection began; (2) time-varying, serotype-specific patterns of
unexplained infections from visitors to the study area or residents that were infected outside
the study area; and (3) constants for scaling mosquito population density at two different time
points during which mosquitoes were collected using different methods. We calibrated these
parameters using a particle filtering algorithm described in detail elsewhere (Table 3) [42].
Simulation experiments
Our primary goal was to quantify bias in VES estimates insofar as they relate to estimates of
individual protection afforded by the vaccine, as defined in our simulation model by PEP. This
individual-level interpretation is significant, because VES estimates from standard methods
represent a weighted average of vaccine effects at the population level. Therefore, whenever the
assumption of homogeneous exposure is not met, VES estimates are specific to exposure pat-
terns in the population where the vaccine was evaluated [22]. To the extent that VES estimates
made in this way might be used to inform projections of vaccination impact in other popula-
tions (due to what is usually a lack of a direct estimate of PEP), understanding the extent of
bias in estimates of PEP based on VES is important [22]. To address this driving question, we
performed three simulation experiments under different assumptions about heterogeneity in
DENV transmission patterns.
1. Baseline scenario. The trial design under the baseline scenario was described in the
Trial Overview and Sample Size sections. In this scenario, the attractiveness of humans to mos-
quitoes was proportional to the human’s body size [11]. The timeframe of the trial ranged one
to three years depending on when 68 virologically-confirmed symptomatic dengue cases were
captured. We simulated 1,000 replicates of this trial with an input PEP = 0.8 and quantified the
bias of the estimated VES relative to the input PEP. We also simulated the trial with an alterna-
tive assumption about the viremia of infected vaccinees, in which their viremia followed that
Biased efficacy estimates in dengue vaccine trials: A simulation study
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of someone experiencing a natural DENV infection. We quantified differences between esti-
mated VES and simulated PEP under both assumptions of viremia of infected vaccinees.
We computed the probability that the point estimate of VES was lower than a specified min-
imum product profile (MPP) below which the vaccine would not be licensed or further
Table 3. Calibrated parameters.
Parameter Reference
Serotype-specific population immunity on 1 Jan. 2000 Fitted to represent estimates of force of infection
[27]
Time-varying, serotype-specific patterns of imported
infections
Fitted to represent estimates of force of infection
[27]
Scaling of mosquito population density Fitted to represent estimates of force of infection
[27]
https://doi.org/10.1371/journal.pone.0210041.t003
Table 2. Fixed parameters of the model.
Parameter Value Reference
Mosquito daily movement probability to a
nearby house
30% [48]
Mosquito daily emergence rates Consistent with time-varying estimates of adult
mosquito death rates and spatiotemporal estimates of
Ae. Aegypti density in Iquitos.
[49,50]
Average interval between blood feeding
events (exponential distribution)
Temperature-dependent [51–53]
Probability of pathogen transmission to
susceptible human conditional on an
infectious mosquito bite
1.0 [54]
Incubation period in the mosquito
(lognormal distribution)
m ¼ f ðTÞ ; s ¼ 0:451754 [55]
Infectiousness—human symptomatic
primary infection
eð  0:204ðt  ti   5:538Þ2=0:999Þ [56]
Infectiousness—human symptomatic
secondary infection
eð  0:383ðt  ti   5:874Þ2=0:999Þ [56]
Infectiousness—human asymptomatic
primary infection
eð  0:25ðt  ti   5:585Þ2=0:999Þ [56]
Infectiousness—human asymptomatic
secondary infection
eð  0:584ðt  ti   4:883Þ2=0:999Þ [56]
Incubation period in humans Captured by time-varying infectiousness curve [55,56]
Human temporary immunity period
(Exponential distribution).
l ¼ 1
686
days  1 [42,57]
Probability of developing symptoms given
primary infection
30% [56]
Probability of developing symptoms for
secondary infection
60% [56]
Probability of developing symptoms for
tertiary and quaternary infections
10% [56]
Probability of severe disease for primary
infection, given the apparition of symptoms
11% [56]
Probability of severe disease for secondary
infection, given the apparition of symptoms
20% [56]
Probability of severe disease for tertiary and
quaternary infections, given the apparition of
symptoms
5% [56]
Human demographic rates Consistent with U.N. estimates [58]
https://doi.org/10.1371/journal.pone.0210041.t002
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developed. We varied the value of MPP (0.1–0.7) and calculated this probability given a PEP
equal to the target product profile (TPP) (VE� 0.8). We varied the value of PEP (0.1–0.95)
and computed the proportion of trials resulting in VES falling below MPP = 0.3.
2. Effects of heterogeneous exposure due to heterogeneous biting. Heterogeneity in the
number of DENV exposures experienced by participants in each trial arm can affect trial
results. In our model, an exposure is defined as a bite from an infected mosquito that would
result in a human infection in the absence of vaccination. Hence, placebo participants can only
experience one exposure before developing infection. Conversely, participants in the vaccine
arm can experience multiple exposures before infection due to the assumption that the vaccine
is leaky. We simulated four scenarios about the nature of heterogeneous exposure, illustrated
in Fig 2, to investigate how different forms of exposure heterogeneity affect VES estimates.
The different forms of exposure heterogeneity that we considered (Fig 2) come about
through:
A. Homogeneous hazard of exposure, in which mosquitoes are bypassed altogether and indi-
viduals are infected directly based on a time-varying rate of DENV infection.
B. Constant attractiveness, in which mosquitoes are equally attracted to all humans for blood
feeding at a location.
C. Attractiveness proportional to body surface area, in which mosquitoes are more likely to
bite humans with larger bodies [11].
D. Heterogeneous attractiveness, in which each individual’s attractiveness is drawn from a
gamma distribution with shape a ¼ 1:43 and rate b ¼ 1, as informed by data from de
Benedictis et al. [12].
In addition to heterogeneity in attractiveness to mosquitoes, heterogeneous exposure in the
transmission model results from spatial heterogeneity in contact between mosquitoes and
humans, due to spatial patterns of mosquito abundance and human mobility. This is true for
all scenarios except A. In scenario A, infections during a trial occur only by a time-varying haz-
ard of DENV infection. We adjusted this hazard to be the same as the force of infection in the
remaining three scenarios so that within the trial the AR would be comparable among scenar-
ios. We compared the distributions of VES estimates under these four scenarios by performing
1,000 simulations, with analogous simulations in each set that had the same sequence of ran-
dom number seeds to minimize differences due to chance across the four scenarios.
3. Effect of increased heterogeneity of exposure due to high transmission intensity.
We hypothesized that phase-III trials in sites with high transmission intensity yield more
biased vaccine efficacy estimates than trials performed with moderate to low transmission
intensity, due to an increased number of exposures in the vaccine arm. Our goal was to quan-
tify the potential magnitude of this effect in our simulated trials by computing bias in VES esti-
mates in a scenario with high transmission intensity. We achieved variation in transmission
intensity by varying mosquito emergence rates, which scale the overall density of adult mos-
quitoes and have a linear effect on the force of infection. Specifically, we doubled mosquito
emergence rates in the high-transmission scenario, and we calculated required sample sizes
separately for each trial to attain the same statistical power for VES estimates under both sce-
narios. With these specifications, we simulated 1,000 replicates for each scenario with paired
random seeds to allow the behavior of the simulations to be as comparable as possible.
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Results
1. Baseline scenario
Analysis of the baseline simulations showed a general pattern of VES underestimating the sim-
ulated value of PEP (0.8) when using VES,IR (0.71) and VES,Cox (0.71). Compared to VES,IR and
VES,Cox, the frailty model slightly reduced bias in its estimate of VES,frailty (0.73). Knowledge of
the number of exposures in each trial arm was associated with a slight overestimation of effi-
cacy by VES,p (0.81) (Fig 3A). Although these patterns held qualitatively across the full range of
assumptions about the extent to which the vaccine protects against infection versus disease
(modulated by the parameter ρ), the magnitude of bias in VES,IR, VES,Cox, and VES,frailty was
somewhat sensitive to ρ (S3 Fig). Specifically, these biases were stronger when protection
derived more from reducing the risk of infection conditional on exposure and less from reduc-
ing the risk of disease conditional on infection (i.e., ρ closer to 1). The slight upward bias of
VES,p by 0.01 was unexpected, because VES,p should be capable of fully accounting for bias due
to heterogeneous exposure [19]. We also noted that the extent of bias was different between
Fig 2. Four distinct assumptions about heterogeneous DENV exposure. Scenario A represents homogeneous
transmission of DENV ignoring mosquitoes and human movement patterns, leading to everyone experiencing the
same hazard of exposure to any serotype of DENV. In scenarios B, C, and D, DENV is transmitted by mosquitoes, and
human and mosquito movement patterns are considered. Scenario B represents homogeneous attractiveness of
different humans to mosquitoes at a given location. Scenario C represents human attractiveness to mosquitoes
proportional to human body size. Scenario D represents heterogeneous human attractiveness to mosquitoes based on a
gamma distribution with shape 1.43 and scale 1, regardless of their body size.
https://doi.org/10.1371/journal.pone.0210041.g002
Biased efficacy estimates in dengue vaccine trials: A simulation study
PLOS ONE | https://doi.org/10.1371/journal.pone.0210041 January 25, 2019 10 / 23
seropositive (Fig 3B) and seronegative (Fig 3C) groups. In particular, bias towards the null was
0.02 higher in the seropositive group for all VES measures (Fig 3B). Even though this was a
small difference, an upward bias in the seronegative group could partially mask the magnitude
of the bias due to heterogeneous exposure in the overall VES estimates.
After reviewing aspects of the simulation model that could have differed between seroposi-
tive and seronegative individuals, we hypothesized that a bias away from the null that is
Fig 3. Overall VES and VES with stratification estimated for 1,000 simulations of the baseline scenario for one site. In this scenario,
attractiveness of humans is proportional to their body size. VES is calculated with four different methods: VES,Cox, VES,IR, VES,CI, and VES,p.
Violin plots on the left panel show the shape of the distribution of VES,Cox estimates. Colored solid lines show the 25, 50, and 75 quantiles
for VES,Cox, VES,p, VES,IR, and VES,frailty (gray, blue, red, and green, respectively). Black solid line represents the true PEP = 1—RRinf|exp
RRdis|inf = 0.8. Left panel corresponds to the assumption of viremia in vaccinated individuals as secondary infections. Right panel
corresponds to the assumption of viremia in vaccinated individuals as a natural infection.
https://doi.org/10.1371/journal.pone.0210041.g003
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distinct from the bias due to heterogeneous exposure occurred as a result of the way in which
we simulated viremia trajectories in infections of vaccinated individuals. Because these infec-
tions were defined as secondary-like infections with shorter viremia periods (S1 Fig), fewer
primary infections in the vaccine arm were detected by the RT-PCR than in the placebo arm.
This resulted in VES estimates being approximately 0.01 higher on average than they would
have been if the viremia trajectories in primary vaccinee infections had been the same as they
were in unvaccinated individuals (Fig 3C and 3F). This bias increased to 0.06 (S2C and S2F
Fig) in a scenario in which RT-PCR was used up to seven days after symptom onset, in con-
trast to the baseline of five days. This effect was apparent for seronegative individuals (for
whom there were differences in RT-PCR sensitivity between vaccinated and unvaccinated) but
not for seropositive individuals (for whom RT-PCR sensitivity was equal for vaccinated and
unvaccinated) (Fig 3B and 3C). We interpret this bias to have occurred because differences in
RT-PCR sensitivity among seronegative trial participants resulted in vaccinated individuals
being perceived to experience an artificially low number of infections. As expected under this
interpretation, this bias disappeared in simulations in which we assumed that RT-PCR sensi-
tivity was the same for vaccinated and unvaccinated individuals (Figs 3F and S2F). Further-
more, these individuals were also protected from infection later in the trial, which was
perceived to result from vaccination but in reality resulted from heterotypic immunity follow-
ing natural infection. Assumptions about viremia did not affect VES estimates for the seroposi-
tive population (Fig 3B and 3E), because their viremia curves were the same for vaccinated and
unvaccinated individuals.
Because differential detectability resulted in a bias away from the null under the baseline
scenario, it had the effect of slightly reducing our estimate of the extent to which heteroge-
neous exposure induced bias toward the null. VES estimates from the seropositive group were
unaffected by the bias due to differential detectability and, therefore, provided a clearer indica-
tion of the extent of bias due to heterogeneous exposure. Across all four measures of VES that
we examined, bias was approximately 0.01 more toward the null in the seropositive group than
in the trial as a whole (Fig 3F vs 3A). This relatively small difference between the overall VES
estimate and the VES estimate for the seropositive group can be attributed to the majority of
trial participants being seropositive (0.6, CI = [0.57,0.63]) and the majority of the cases coming
from seropositive individuals (0.66, CI = [0.55, 0.76]). Consequently, the extent to which bias
away from the null due to differential detectability counteracts bias toward the null due to het-
erogeneous exposure would be expected to differ in trials in which the proportion of seroposi-
tive trial participants differs from our simulations. In summary, using conventional measures
of VES that do not account for these biases (i.e., VES,Cox and VES,IR), analyses of our simula-
tions with PEP = 0.8 resulted in VES estimates that were biased toward the null by approxi-
mately 0.09 due to heterogeneous exposure. Estimates of VES were biased away from the null
by as much as 0.01 due to differential detectability of primary infections between vaccinated
and unvaccinated individuals.
As one way to place these biases into context, we examined the proportion of simulated tri-
als in which the vaccine would not have been licensed on the basis of the VES point estimate
falling below the minimum product profile (MPP). For an MPP of 0.3, this probability
depended on the VES measure used at different values of PEP. This probability was always
lower for the VES,p measure, compared to the other three measures used (Fig 4). For instance,
for PEP = 0.4, the vaccine would not have been licensed in nearly 40% of simulated trials on
the basis of the point estimates of VES,Cox, VES,frailty, and VES,IR. It would not have been
licensed in almost all simulated trials if the lower bound of the confidence interval of the VES
estimates were used as a criterion for licensure. For PEP = 0.4, the probability of a vaccine not
being licensed on the basis of the point estimate of VES,p was only around 0.2, and around 0.8
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when based on the lower bound of the confidence interval. Across these and other instances,
there was a lower probability of rejecting a vaccine with PEP exceeding MPP whenever PEP
was farther away from MEP and when bias toward the null was less severe.
2. Effects of heterogeneous exposure due to heterogeneous biting
The scenario with homogeneous hazard of exposure was associated with less bias toward the
null compared to the three scenarios that allowed for some form of heterogeneous hazard of
exposure (Fig 5A compared with Fig 5B–5D). When the hazard of exposure was homoge-
neous, VES,p and VES,frailty were approximately equal to PEP (VES,p = 0.8, VES,frailty = 0.79),
and the other two measures slightly underestimated it (VES,Cox = 0.77, VES,IR = 0.77) (Fig 5A).
As in the baseline scenario described above, overall estimates of VES reflect a combination of
distinct VES estimates for the seropositive and seronegative groups, due to a bias away from
the null resulting from differential detectability of primary infections among vaccinated and
unvaccinated individuals. Among seropositive individuals, VES,p was the only measure that
Fig 4. Probability of not licensing a vaccine with MPP = 0.3 at different input PEP values. Solid lines represent the
probability of rejection calculated as the proportion of simulations where the lower bound of the confidence interval of
VES was below MPP. Dotted lines represent the probability of rejection calculated as the proportion of simulations
where the mean estimate of VES was below MPP.
https://doi.org/10.1371/journal.pone.0210041.g004
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appeared to be unbiased (blue in Fig 6A). The other three measures exhibited some bias
toward the null (red, gray, green in Fig 6A), because a homogeneous hazard of exposure still
results in some degree of heterogeneity in the numbers of exposures that individuals experi-
ence (S4 Fig). Among seronegative individuals in the vaccinated group, the downward bias of
heterogeneous exposure canceled out with the upward bias of lower detectability of primary
infections and VES,Cox and VES,IR showed unbiased estimates of VES, while VES,p and VES,frailty
displayed bias away from the null for this group (Fig 6E).
Fig 5. Vaccine efficacy in four scenarios about heterogeneous exposure to DENV for seropositive and seronegative individuals. Violin
plots show the shape of the distribution of VES,Cox estimates. The colored solid lines show the 25, 50, and 75 quantiles for VES,Cox, VES,p, VES,
IR, and VES,frailty (gray, blue, red, and green, respectively). Black solid line represents the individual input of vaccine efficacy: VE = 1 –PEP = 1
—RRinf|exp RRdis|inf = 0.8. The left panel corresponds to VES in seropositives and the right panel corresponds to the VES in seronegatives.
https://doi.org/10.1371/journal.pone.0210041.g005
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The scenarios with heterogeneous hazard of exposure resulted in a larger bias toward the
null when using VES,Cox, VES,IR, and VES,frailty than when using VES,p (blue closer to PEP than
gray, red, or green in Fig 5B–5D). These estimates were all within approximately 0.01 of each
other under all three scenarios that allowed for heterogeneous attractiveness of humans to
mosquitoes (right three columns in S5 Fig), as opposed to a difference of approximately 0.05
between the homogeneous scenario and each of the three heterogeneous scenarios (left three
columns in S5 Fig). This indicates that a substantial degree of heterogeneity in exposure
derives from spatial heterogeneity in mosquito density among different houses and
Fig 6. Vaccine efficacy in four scenarios about heterogeneous exposure to DENV for seropositive and seronegative individuals. Violin
plots show the shape of the distribution of VES,Cox estimates. The colored solid lines show the 25, 50, and 75 quantiles for VES,Cox,
VES,p, VES,IR, and VES,frailty (gray, blue, red, and green, respectively). Black solid line represents the individual input of vaccine
efficacy: VE = 1 –PEP = 1—RRinf|exp RRdis|inf = 0.8. The left panel corresponds to VES in seropositives and the right panel corresponds
to the VES in seronegatives.
https://doi.org/10.1371/journal.pone.0210041.g006
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heterogeneity in how individual humans sample that heterogeneity through their movement
patterns, whereas relatively little derives from heterogeneous blood feeding within a single
house. Examination of the distribution of the number of exposures experienced by trial partici-
pants further supports this conclusion, with higher variance in the number of exposures under
the three heterogeneous scenarios than under the homogeneous scenario (S4 Fig).
3. Effect of increased heterogeneity of exposure due to high transmission
intensity
Higher transmission intensity increased the bias in VES estimates even further toward the null
because of a higher chance of repeated exposure in the population at risk, which increased het-
erogeneity in the number of exposures. This increased heterogeneity also affected the scenario
with homogeneous hazard of infection (Fig 7A), because homogeneity in the hazard of expo-
sure does not ensure homogeneity in the number of exposures that individuals experience dur-
ing the trial. Some individuals in this scenario were exposed up to five times during the trial
(S6 Fig), compared to a maximum of three exposures under the baseline transmission intensity
assumptions (S4 Fig). Under the homogeneous hazard scenario, the frailty model did a rela-
tively good job of reducing bias toward the null (VES,frailty = 0.77, compared with VES,Cox =
0.64, VES,IR = 0.64), but it was less successful at doing so under the three heterogeneous hazard
scenarios (VES,frailty = 0.69, compared with VES,Cox = 0.66, VES,IR = 0.66) (Fig 7B–7D).
Accounting for exposure with VES,p resulted in unbiased estimates.
Discussion
Our results indicate that, under the assumption of a leaky vaccine (i.e., provides partial protec-
tion to all vaccinated individuals), VES is consistently underestimated by standard measures
that do not account for the repeated, heterogeneous nature of DENV exposure. For instance,
heterogeneity in exposure violates an assumption required by the Cox model to ensure unbi-
ased estimates of VES [22]. Heterogeneous exposure has the effect of reducing efficacy because
some individuals are highly protected from infection in both arms of the study, which makes
the placebo arm of the study more similar to the vaccine arm. Under the default assumptions
and scenarios that we examined, we observed that the extent of bias toward the null as a result
of heterogeneous exposure could be as great as 21% of the value of simulated PEP, depending
on the extent to which the vaccine protects against infection or disease. Depending on the sim-
ulated value of PEP and how close it was to MPP, we found that different methods for estimat-
ing VES have implications for the possibility of not licensing a vaccine that has desirable
properties but is not perceived as such due to bias from heterogeneous exposure.
One possibility for mitigating bias due to heterogeneous exposure that we examined was
incorporating a frailty expression, which accounts for unmeasured heterogeneity as a random
effect [21], into our Cox survival analysis of simulated trial data. This step did help reduce VES
bias, particularly under scenarios in which heterogeneity was more extreme. Although our
results indicate that incorporation of a frailty term into estimation of VES from dengue vaccine
trial data could help reduce bias toward the null, a caveat is that biased estimates of VES can
still be obtained when the frailty distribution is not accurately specified [21]. Also, at high
degrees of censoring, non-identifiability of the model parameters can be an issue with frailty
models [21].
Another possibility for mitigating bias due to heterogeneous exposure is to incorporate
information about the number of exposures in each trial arm. This approach successfully elim-
inated bias due to heterogeneous exposure in our simulations. A disadvantage, however, is that
additional information pertinent to the number of exposures in each trial arm must be
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collected. In a real trial, doing so would amount to obtaining estimates of the total number of
bites by infectious mosquitoes on all individuals in each trial arm. Even as an average across
many individuals in a trial arm, estimating entomological risk of DENV infection is not
straightforward [59]. Challenges to doing so include significant spatiotemporal heterogeneity
in DENV transmission activity [7], shifting hotspots of mosquito density over timescales
Fig 7. Overall VES estimates from 1,000 simulations of each setting with different assumptions about heterogeneous exposure in a
high-intensity setting. Sample size was adjusted to 800 participants to achieve 90% statistical power in a higher transmission setting. Each
row represents an assumption about heterogeneous exposure to DENV: homogeneous hazard of exposure, constant attractiveness of
humans, attractiveness of humans based on body size, and attractiveness of humans based on a gamma distribution (shape = 1.43 and
scale = 1). VES is calculated with four different methods: VES,Cox, VES,IR, VES,CI, and VES,p. Violin plots on the left panel show the shape of
the distribution of VES,Cox estimates. Colored solid lines show the 25, 50, and 75 quantiles for VES,Cox, VES,p, VES,IR, and VES,frailty (gray,
blue, red, and green, respectively). Black solid line represents the true PEP = 1—RRinf|exp RRdis|inf = 0.8. Right panel corresponds to the
number of cases captured in the trial.
https://doi.org/10.1371/journal.pone.0210041.g007
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shorter than a trial [15], and the fact that individuals are subject to mosquito bites and DENV
exposure at the numerous locations they visit during their daily routines [60]. Unfortunately,
these are precisely the forms of heterogeneity that our results indicate contribute most to bias
in VES estimates, rendering VES,p an ideal, but impractical, solution to mitigate bias due to het-
erogeneous exposure.
We also found an unexpected source of bias for seronegative individuals. This bias comes
from our assumption of shorter viremia periods in primary infections for vaccinated com-
pared to unvaccinated individuals. This assumption resulted in fewer detected cases between
follow-up visits in the vaccine arm than in the placebo arm. As a consequence, estimates of
VES in the seronegative group were biased away from the null. This bias was relatively small
when the RT-PCR was used up to five days after symptom onset, as advised by the Centers for
Disease Control and Prevention [38]. Not adhering to these guidelines could, however, result
in larger bias away from the null, which we observed when we allowed use of RT-PCR up to
seven days after symptom onset. Ignoring this type of bias could result in reducing the magni-
tude of the bias toward the null from heterogeneous exposure. Doing so may be acceptable
from the perspective of estimating overall VES, but it has the potential to bias estimates of VES
for seronegatives above that of seropositives. For biological reasons [61], estimates for Deng-
vaxia indicate that VES is higher for seropositives than seronegatives [29]. If analyses of Deng-
vaxia trial data are subject to this bias from differential detectability, that would indicate that
the estimated difference in VES between seropositives and seronegatives could be somewhat
greater than currently thought.
There are also sources of bias other than heterogeneous exposure and differential detect-
ability that could manifest in dengue vaccine trials. For instance, infections among trial partici-
pants that go undetected could result in bias toward the null. This could occur if analyses of
symptomatic endpoints fail to consider that unobserved infections in the placebo arm differen-
tially reduce person-time at risk, increasing the apparent similarity between outcomes in vac-
cine and placebo arms [62]. This effect may have been moderated in our analyses because
conditions that promote it—protection deriving from blocking infection rather than amelio-
rating disease, high baseline hazard—were not in effect to a large degree. Nonetheless, unde-
tected DENV infections are common [63] and can cause other problems for the interpretation
of dengue vaccine trial data [64]. Heterogeneity in susceptibility is a related source of bias that
causes bias toward the null for reasons similar to why unobserved infections do [65]. Although
pre-enrollment serological testing could be used to classify individuals as seropositive or sero-
negative for any dengue vaccine trial, it is likely that the serotype(s) to which an individual is
susceptible would be undefined, which could be considered a potential source of unmeasured
heterogeneity in susceptibility.
Recent decades have seen great elaboration of theory for vaccine trial design and analysis
[19], which has increasingly embraced heterogeneity in data-generating processes such as
exposure. This growing body of literature has resulted in a number of principles about poten-
tial sources of bias in VES estimation, highlighted through simulation experiments that have
tended to make use of relatively simple models [66]. Because our primary goal in this study
was to quantify the extent of a known bias for a specific disease, we opted for an agent-based
model that uses highly detailed data to realistically simulate effects of heterogeneous exposure.
In addition to achieving this explicit goal of our study, we uncovered an unexpected source of
bias that could have implications for interpretation of Dengvaxia trial data. This discovery
emerged from our analyses as a result of including detail in model structure beyond what was
minimally necessary to meet our primary goal of quantifying bias due to heterogeneous expo-
sure. This work adds to a growing list of applications of dynamic transmission models to
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planning for dengue vaccine trials (this study), interpreting their results [35,61], and making
projections of their impacts when deployed at the population level [42,46,47,61].
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trial. The four simulations used the same random number seed to increase comparability
among simulations.
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S5 Fig. Pairwise difference of VES,Cox between different scenarios about heterogeneous
exposure. Each scenario was simulated 1,000 times with the same sequence of random number
seeds to minimize differences caused by stochastic effects.
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S6 Fig. Distribution of exposures within the vaccine arm of the trial under different sce-
narios about heterogeneous exposure with high transmission intensity. The height of the
bars represents the relative frequency of the number of exposures in the vaccine arm for a
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